In the treatment of breast cancer, a PARP inhibitor was used in combination with an initial kinase inhibitor; in the treatment of ovarian cancer, doxorubicin was used to enhance the therapeutic effect of the PARP inhibitor; and in the treatment of pancreatic cancer, the effect of cisplatin with a PARP inhibitor was investigated [10]. The gene discussed is PARP1; the disease is familial pancreatic carcinoma.